Gan HK, et al. - This study was planned to assess the safety and pharmacokinetics of depatux-m, either in combination with temozolomide in newly diagnosed or recurrent glioblastoma or as monotherapy in recurrent glioblastoma. As per findings, depatux-m alone or in combination with temozolomide had an acceptable safety and pharmacokinetic profile. Further studies evaluating its efficacy in newly diagnosed (NCT02573324) and recurrent glioblastoma (NCT02343406) are currently underway.